Agilent Technologies (Oligo GMP)

Boulder, CO
Reagent / Material Supplier
Oligonucleotide
1 confirmed programs · 1 sponsors · Last scored 2026-04-02
74.2
Signal Score
✓ FDA Inspections (1) ✓ Clinical Trials (1) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Agilent Technologies (Oligo GMP)

Signal Score
74.2/100 (as of 2026-04-02)
Quality Compliance
100.0/100
Headquarters
Boulder, CO
Modalities
Oligonucleotide
Active Programs
1 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-06-18)
Operations 60.0
1 active programs across 1 sponsors
Modalities: Oligonucleotide
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
1 active programs across 1 sponsors · Modalities: Oligonucleotide · 1 programs in advanced phases (Phase 2/3)
Programs 1
Sponsors1
ModalitiesOligonucleotide
1 active programs across 1 sponsors
Modalities: Oligonucleotide
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT02452697 Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From... PHASE2 Unknown
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability 68.0
Parent company: Agilent Technologies
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Agilent Technologies
Financial assessment: 68.0/100
Capacity 53.0
1 manufacturing site: Boulder, CO
Modalities: Oligonucleotide
Capacity assessment: 53.0/100
Sites: Boulder, CO
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Boulder, CO
Modalities: Oligonucleotide
Capacity assessment: 53.0/100

FDA Inspection History

2025-06
NAI VAI OAI
Date Site Type Observations Classification
2025-06-18 Frederick, Colorado Drug Quality Assurance No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Apr 05, 2026

Clinical Activity 1 studies

NCT02452697 Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors... PHASE2 Unknown
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Oligonucleotide CDMOs →

Similar CDMOs

Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 81.6
mRNA, Oligonucleotide, Biologics
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV
Bachem
Bubendorf, CH
Signal Score: 83.4
Oligonucleotide
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
Kaneka Eurogentec
Seraing, BE
Signal Score: 80.3
mRNA, Plasmid, Oligonucleotide